Form 4: Cytokinetics CEO Robert Blum Sells 22,500 Shares Under 10b5-1 Plan

Cytokinetics' CEO, Robert I. Blum, sold 22,500 shares of common stock at $48.85 per share on June 4, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On June 4, 2024, Robert I. Blum, the President and CEO of Cytokinetics Inc., sold 22,500 shares of the company's common stock.
• The sale was executed at a price of $48.85 per share.
• This transaction was conducted under a pre-arranged trading plan that complies with Rule 10b5-1(c) of the Securities Exchange Act, which was established on March 5, 2024.
• Following the transaction, Blum directly owns 439,145 shares of Cytokinetics' common stock.
• Additionally, Blum indirectly owns 2,083 shares through The Bridget Blum 2003 Irrevocable Trust and 2,083 shares through The Brittany Blum 2003 Irrevocable Trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged 10b5-1 plan. It doesn't necessarily indicate a positive or negative outlook on the company.

Industry Context

Executive stock sales are a common occurrence, and sales under 10b5-1 plans are generally viewed as less indicative of the executive's sentiment on the company's prospects, as the plans are pre-arranged.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, but given it's under a 10b5-1 plan, it's unlikely to cause significant concern.

Key Dates